Trial Profile
Pharmacokinetics,Safety and Immunogenicity of ASKB1202 in Chinese Healthy Subjects: a Randomized, Double-blinded, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Jiangsu Aosaikang Pharmaceutical
- 19 Apr 2017 New trial record